Mar 17, 2021 / 05:10PM GMT
Mark Alan Breidenbach - Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
Hi, everyone. Thanks so much for joining us on day 2 of Oppenheimer's 31st Annual Healthcare Conference. My name is Mark Breidenbach. I'm part of Oppenheimer's biotech equity research team. And this afternoon, I'm pleased to be hosting a fireside chat with Iovance, which is developing autologous cell therapies for cancer. And we're joined by the company's CEO, Maria Fardis. We'll be sure to try to leave a few minutes at the end for Q&A. So I would encourage anyone in the audience who has a question to make use of the question box underneath your video.
So thank you for joining us, everyone, and let's go ahead and get started.
Maria, for the uninitiated, maybe you can give us a very brief introduction to the company and its core technology platform and a very quick overview of its lead programs.
Maria Fardis - Iovance Biotherapeutics, Inc. - CEO, President & Director
Absolutely. Thank you, Mark, and thank you for hosting us
Iovance Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers